Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

News SummaryMost relevantAll newsSector news 

MORPHOSYS : to Present at Upcoming Investor Conference

02/02/2011 | 10:05am US/Eastern

MorphoSys AG / MorphoSys to Present at Upcoming Investor Conference Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Chief Executive Officer Dr Simon Moroney will present at the upcoming Société Générale Healthcare and Biotechnology Conference in Paris.


Société Générale Healthcare and Biotechnology Conference
Date: February 9, 2011
Venue: Paris, France
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG


A PDF version of the company presentation is provided at www.morphosys.com:





+++MorphoSys will publish its Full Year 2010 Results on February 24, 2011+++



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys. arYlaTM is a trademark of MorphoSys.



This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.





For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122


Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454


Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332




Press Release:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


React to this article
Latest news on MORPHOSYS AG
09/23 MORPHOSYS : Publishes Update on MOR202 in Multiple Myeloma at 15th International..
09/17 MORPHOSYS : Patent Application Titled "Treatment for Rheumatoid Arthritis" Publi..
09/10 MORPHOSYS : "Combinations and Uses Thereof" in Patent Application Approval Proce..
09/09 MORPHOSYS : Provides an Update on its Proprietary Development Portfolio
09/08 MORPHOSYS : Provides an Update on its Proprietary Development Portfolio
09/08 MORPHOSYS : Provides an Update on its Proprietary Development Portfolio
09/05 MORPHOSYS : to Present at Six Upcoming Conferences
09/04 MORPHOSYS : to Present at Six Upcoming Conferences
08/26 MORPHOSYS : Enters into Agreement with Immatics Biotech
08/26 MORPHOSYS : and Immatics Biotechnologies Enter Strategic Alliance in Immuno-onco..
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Income Statement Evolution
More Financials